The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
To create leading company developing medicines targeting metalloenzymes
Allam was serving recently as the CEO at Public Investment Fund
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
Follows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategy
Pemetrexed for injection is indicated for the treatment of Antineoplastics (medications used to treat cancer)
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
In clinical trials, treatment proved more effective than other therapies evaluated
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)